Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure

IF 4.3 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Seminars in liver disease Pub Date : 2023-12-15 DOI:10.1055/s-0043-1776773
MohammadMahdi Saeidinejad, Ahmed Elshabrawi, Supachaya Sriphoosanaphan, Fausto Andreola, Gautam Mehta, Banwari Agarwal, Rajiv Jalan
{"title":"Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure","authors":"MohammadMahdi Saeidinejad, Ahmed Elshabrawi, Supachaya Sriphoosanaphan, Fausto Andreola, Gautam Mehta, Banwari Agarwal, Rajiv Jalan","doi":"10.1055/s-0043-1776773","DOIUrl":null,"url":null,"abstract":"<p>Acute-on-chronic liver failure (ACLF), a clinical syndrome that can develop at any stage in the progression of cirrhotic liver disease, is characterized by an acute decompensation in liver function with associated multiorgan failure and high short-term mortality. Current evidence points to ACLF being reversible, particularly in those at the lower end of the severity spectrum. However, there are no specific treatments for ACLF, and overall outcomes remain poor. Expedited liver transplantation as a treatment option is limited by organ shortage and a lack of priority allocation for this indication. Other options are therefore urgently needed, and our improved understanding of the condition has led to significant efforts to develop novel therapies. In conclusion, this review aims to summarize the current understanding of the pathophysiological processes involved in the onset, progression, and recovery of ACLF and discuss novel therapies under development.</p> ","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"49 1","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in liver disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0043-1776773","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Acute-on-chronic liver failure (ACLF), a clinical syndrome that can develop at any stage in the progression of cirrhotic liver disease, is characterized by an acute decompensation in liver function with associated multiorgan failure and high short-term mortality. Current evidence points to ACLF being reversible, particularly in those at the lower end of the severity spectrum. However, there are no specific treatments for ACLF, and overall outcomes remain poor. Expedited liver transplantation as a treatment option is limited by organ shortage and a lack of priority allocation for this indication. Other options are therefore urgently needed, and our improved understanding of the condition has led to significant efforts to develop novel therapies. In conclusion, this review aims to summarize the current understanding of the pathophysiological processes involved in the onset, progression, and recovery of ACLF and discuss novel therapies under development.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
治疗急性慢性肝衰竭的新疗法
急性慢性肝功能衰竭(ACLF)是一种临床综合征,可发生在肝硬化进展的任何阶段,其特点是肝功能急性失代偿,伴有多器官功能衰竭和较高的短期死亡率。目前的证据表明,ACLF 是可逆的,尤其是对于严重程度较轻的患者。然而,目前还没有治疗 ACLF 的特效疗法,总体疗效仍然不佳。快速肝移植作为一种治疗方法,受到器官短缺和缺乏优先分配给这一适应症的限制。因此,我们急需其他治疗方案,而我们对该病的深入了解也促使我们为开发新型疗法做出了巨大努力。总之,本综述旨在总结目前对 ACLF 发病、进展和恢复所涉及的病理生理过程的理解,并讨论正在开发的新型疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in liver disease
Seminars in liver disease 医学-胃肠肝病学
CiteScore
8.20
自引率
2.40%
发文量
38
期刊介绍: Seminars in Liver Disease is a quarterly review journal that publishes issues related to the specialties of hepatology and gastroenterology. As the premiere review journal in the field, Seminars in Liver Disease provides in-depth coverage with articles and issues focusing on topics such as cirrhosis, transplantation, vascular and coagulation disorders, cytokines, hepatitis B & C, Nonalcoholic Steatosis Syndromes (NASH), pediatric liver diseases, hepatic stem cells, porphyrias as well as a myriad of other diseases related to the liver. Attention is also given to the latest developments in drug therapy along with treatment and current management techniques. Seminars in Liver Disease publishes commissioned reviews. Unsolicited reviews of an exceptional nature or original articles presenting remarkable results will be considered, but case reports will not be published.
期刊最新文献
Role of Complement in Liver Diseases. LncRNA, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology. Wilson Disease: Novel Diagnostic and Therapeutic Approaches. Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease. HBV Biomarkers and Their Role in Guiding Treatment Decisions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1